Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06266611 · ClinicalTrials.gov registry record · Phase 2

Cannabis for Palliative Care in Cancer

A Phase 2 study of Depression and Pain, sponsored by University of Colorado, Boulder.

Recruiting
Registry status
Phase 2
Development phase
185
Enrollment target
1
Study location

NCT06266611: Recruiting Phase 2 study of Depression and Pain, sponsored by University of Colorado, Boulder.

NCT06266611 is a Phase 2 study of Depression and Pain that is actively recruiting participants, run by University of Colorado, Boulder. The registered enrollment target is 185 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06266611, a Phase 2 study of Depression and Pain, is actively recruiting participants, sponsored by University of Colorado, Boulder.

RECRUITING
Registry status
Phase 2
Development phase
185 participants
Enrollment target
1
Study location

Study Summary

Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research on cannabis use in the cancer context is required. In this endeavor, the present study seeks to compare the use of hemp-derived CBD (Cannabidiol) with and without THC (Delta-9-tetrahydrocannabinol) versus placebo on measures of sleep, pain, mood, subjective and objective cognitive functioning, and quality of life within 185 cancer patients.

Primary Outcome

PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Interference. Total scores are between 8 and 40, with higher scores meaning more pain interference.

Interventions

  • DRUG Placebo
  • DRUG fsCBD Cannabidiol
  • DRUG bsCBD Cannabidiol

Study Locations (1)

Colorado

  • Anschutz Health Sciences Building - Aurora

Trial Details

FieldValue
Enrollment Target 185 participants
Start Date 2024-09-16
Est. Completion 2028-06-30
Phase Phase 2
University of Colorado, Boulder

69 total trials

What NCT06266611 shows while recruiting

NCT06266611 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (76% lower).

The record links to 4 conditions, with Depression appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06266611 reports a single indexed study location in Colorado.

Frequently Asked Questions

What is clinical trial NCT06266611 about?

NCT06266611 is a clinical study titled "Cannabis for Palliative Care in Cancer". Many cancer patients suffer from pain, sleep, and mood problems and are using cannabis to relieve these symptoms. Cannabis may provide such relief but may also produce negative side effects including cognitive impairment, an especially problematic issue for cancer patients, indicating more research ...

What is the current status of trial NCT06266611?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 185 participants. The study started on 2024-09-16. Estimated completion is 2028-06-30.

What conditions does trial NCT06266611 study?

This clinical trial studies the following conditions: Depression, Pain, Anxiety, Sleep.

What interventions are being tested in trial NCT06266611?

The interventions under investigation include: Placebo (DRUG), fsCBD Cannabidiol (DRUG), bsCBD Cannabidiol (DRUG).

Who is sponsoring clinical trial NCT06266611?

This trial is sponsored by University of Colorado, Boulder, which has 69 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06266611 being conducted?

This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06266611's enrollment target sits among peer trials

185 220th of 679 higher than 459 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04041154 · 185 participants · NA

    Behavioral and Neural Representations of Subjective Effort Cost

  • NCT04484272 · 185 participants · NA

    A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease

  • NCT05020860 · 185 participants · Phase 2

    Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

  • NCT05793541 · 185 participants · NA

    Just-in-time Interventions for Reducing Short-term Suicide Risk

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06266611, the US trial registry maintained by the National Library of Medicine. NCT06266611 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.